MEDIFAST INC (MED) Stock Fundamental Analysis
USA - NYSE:MED - US58470H1014 - Common Stock
12.02 USD
-0.12 (-0.99%)
12.02 USD
0 (0%)
MED gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 34 industry peers in the Personal Care Products industry. While MED has a great health rating, its profitability is only average at the moment. MED is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year MED was profitable.
MED had a positive operating cash flow in the past year.
MED had positive earnings in each of the past 5 years.
MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of 1.35%, MED perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
MED has a Return On Equity (1.68%) which is comparable to the rest of the industry.
MED's Return On Invested Capital of 0.66% is in line compared to the rest of the industry. MED outperforms 41.18% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MED is significantly above the industry average of 12.77%.
The 3 year average ROIC (38.03%) for MED is well above the current ROIC(0.66%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | 1.68% | ||
| ROIC | 0.66% |
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)38.03%
ROIC(5y)46.7%
1.3 Margins
With a Profit Margin value of 0.76%, MED perfoms like the industry average, outperforming 47.06% of the companies in the same industry.
MED's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 0.46%, MED is in line with its industry, outperforming 41.18% of the companies in the same industry.
In the last couple of years the Operating Margin of MED has declined.
MED's Gross Margin of 73.84% is fine compared to the rest of the industry. MED outperforms 76.47% of its industry peers.
MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.46% | ||
| PM (TTM) | 0.76% | ||
| GM | 73.84% |
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), MED is creating value.
MED has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MED has less shares outstanding
MED has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.94 indicates that MED is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.94, MED is in the better half of the industry, outperforming 79.41% of the companies in the same industry.
There is no outstanding debt for MED. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.94 |
ROIC/WACC0.08
WACC8.75%
2.3 Liquidity
MED has a Current Ratio of 4.47. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of MED (4.47) is better than 91.18% of its industry peers.
MED has a Quick Ratio of 3.82. This indicates that MED is financially healthy and has no problem in meeting its short term obligations.
MED's Quick ratio of 3.82 is amongst the best of the industry. MED outperforms 91.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.47 | ||
| Quick Ratio | 3.82 |
3. Growth
3.1 Past
MED shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.18%.
Measured over the past years, MED shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -20.59% on average per year.
Looking at the last year, MED shows a very negative growth in Revenue. The Revenue has decreased by -37.62% in the last year.
Measured over the past years, MED shows a decrease in Revenue. The Revenue has been decreasing by -3.33% on average per year.
EPS 1Y (TTM)-87.18%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-76.09%
Revenue 1Y (TTM)-37.62%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-37.38%
3.2 Future
The Earnings Per Share is expected to decrease by -64.21% on average over the next years. This is quite bad
Based on estimates for the next years, MED will show a very negative growth in Revenue. The Revenue will decrease by -23.25% on average per year.
EPS Next Y-146.27%
EPS Next 2Y-64.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-36.56%
Revenue Next 2Y-23.25%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MED is valuated rather expensively with a Price/Earnings ratio of 22.26.
MED's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 26.11. MED is around the same levels.
The Forward Price/Earnings Ratio is negative for MED. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.26 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -5.75 |
4.3 Compensation for Growth
MED has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as MED's earnings are expected to decrease with -64.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-64.21%
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 9.97%, MED is a good candidate for dividend investing.
MED's Dividend Yield is rather good when compared to the industry average which is at 5.96. MED pays more dividend than 97.06% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.37, MED pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 9.97% |
5.2 History
The dividend of MED decreases each year by -53.42%.
MED has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-53.42%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
MED pays out 5.39% of its income as dividend. This is a sustainable payout ratio.
The Dividend Rate of MED has been decling, while earnings will also be declining. This means the current dividend is most likely not sustainable.
DP5.39%
EPS Next 2Y-64.21%
EPS Next 3YN/A
12.02
-0.12 (-0.99%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners79.62%
Inst Owner Change0.03%
Ins Owners3.3%
Ins Owner Change5.24%
Market Cap132.10M
Revenue(TTM)480.45M
Net Income(TTM)3.64M
Analysts46.67
Price Target15.3 (27.29%)
Short Float %19.62%
Short Ratio13.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 9.97% |
Yearly Dividend0.07
Dividend Growth(5Y)-53.42%
DP5.39%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)126.59%
Min EPS beat(2)54.16%
Max EPS beat(2)199.01%
EPS beat(4)4
Avg EPS beat(4)160.04%
Min EPS beat(4)54.16%
Max EPS beat(4)225.1%
EPS beat(8)6
Avg EPS beat(8)101.41%
EPS beat(12)10
Avg EPS beat(12)89.05%
EPS beat(16)13
Avg EPS beat(16)68.5%
Revenue beat(2)2
Avg Revenue beat(2)6.41%
Min Revenue beat(2)4.07%
Max Revenue beat(2)8.75%
Revenue beat(4)4
Avg Revenue beat(4)4.85%
Min Revenue beat(4)3.13%
Max Revenue beat(4)8.75%
Revenue beat(8)7
Avg Revenue beat(8)2.63%
Revenue beat(12)11
Avg Revenue beat(12)4.12%
Revenue beat(16)14
Avg Revenue beat(16)3.32%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-30%
EPS NY rev (1m)0%
EPS NY rev (3m)7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.79%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.26 | ||
| Fwd PE | N/A | ||
| P/S | 0.27 | ||
| P/FCF | N/A | ||
| P/OCF | 31.81 | ||
| P/B | 0.61 | ||
| P/tB | 0.61 | ||
| EV/EBITDA | -5.75 |
EPS(TTM)0.54
EY4.49%
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)0.38
OCFY3.14%
SpS43.72
BVpS19.65
TBVpS19.65
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.45
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | 1.68% | ||
| ROCE | 1% | ||
| ROIC | 0.66% | ||
| ROICexc | 2.44% | ||
| ROICexgc | 2.44% | ||
| OM | 0.46% | ||
| PM (TTM) | 0.76% | ||
| GM | 73.84% | ||
| FCFM | N/A |
ROA(3y)26.08%
ROA(5y)31.33%
ROE(3y)47.66%
ROE(5y)57.89%
ROIC(3y)38.03%
ROIC(5y)46.7%
ROICexc(3y)95.28%
ROICexc(5y)N/A
ROICexgc(3y)95.28%
ROICexgc(5y)N/A
ROCE(3y)57.45%
ROCE(5y)70.54%
ROICexgc growth 3Y-42.96%
ROICexgc growth 5Y-39.1%
ROICexc growth 3Y-42.96%
ROICexc growth 5Y-39.1%
OM growth 3Y-38.9%
OM growth 5Y-24.01%
PM growth 3Y-68.15%
PM growth 5Y-49.83%
GM growth 3Y-0.04%
GM growth 5Y-0.38%
F-Score5
Asset Turnover1.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 47.98% | ||
| Cap/Sales | 1.37% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 26.07% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.47 | ||
| Quick Ratio | 3.82 | ||
| Altman-Z | 4.94 |
F-Score5
WACC8.75%
ROIC/WACC0.08
Cap/Depr(3y)86.65%
Cap/Depr(5y)168.74%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.15%
Profit Quality(3y)359.98%
Profit Quality(5y)250.42%
High Growth Momentum
Growth
EPS 1Y (TTM)-87.18%
EPS 3Y-47.33%
EPS 5Y-20.59%
EPS Q2Q%-76.09%
EPS Next Y-146.27%
EPS Next 2Y-64.21%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-37.62%
Revenue growth 3Y-26.64%
Revenue growth 5Y-3.33%
Sales Q2Q%-37.38%
Revenue Next Year-36.56%
Revenue Next 2Y-23.25%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-95.63%
EBIT growth 3Y-55.18%
EBIT growth 5Y-26.54%
EBIT Next Year-105.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-101.21%
FCF growth 3Y-34.4%
FCF growth 5Y-25.51%
OCF growth 1Y-98.06%
OCF growth 3Y-36.26%
OCF growth 5Y-21.91%
MEDIFAST INC / MED FAQ
What is the ChartMill fundamental rating of MEDIFAST INC (MED) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MED.
What is the valuation status for MED stock?
ChartMill assigns a valuation rating of 1 / 10 to MEDIFAST INC (MED). This can be considered as Overvalued.
What is the profitability of MED stock?
MEDIFAST INC (MED) has a profitability rating of 6 / 10.
Can you provide the PE and PB ratios for MED stock?
The Price/Earnings (PE) ratio for MEDIFAST INC (MED) is 22.26 and the Price/Book (PB) ratio is 0.61.
What is the earnings growth outlook for MEDIFAST INC?
The Earnings per Share (EPS) of MEDIFAST INC (MED) is expected to decline by -146.27% in the next year.